Immuneering Corporation

NasdaqGM IMRX

Immuneering Corporation Cash and Short-Term Investments for the quarter ending September 30, 2024: USD 50.66 M

Immuneering Corporation Cash and Short-Term Investments is USD 50.66 M for the quarter ending September 30, 2024, a -47.91% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Immuneering Corporation Cash and Short-Term Investments for the quarter ending September 30, 2023 was USD 97.24 M, a -17.03% change year over year.
Immuneering Corporation Cash and Short-Term Investments for the quarter ending September 30, 2022 was USD 117.20 M, a -21.60% change year over year.
Immuneering Corporation Cash and Short-Term Investments for the quarter ending September 30, 2021 was USD 149.48 M.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqGM: IMRX

Immuneering Corporation

CEO	Dr. Benjamin J. Zeskind M.B.A., Ph.D.
IPO Date	July 30, 2021
Location	United States
Headquarters	245 Main Street
Employees	66
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Key trends

Past 5 years